IIBYT   23944
INSTITUTO DE INVESTIGACIONES BIOLOGICAS Y TECNOLOGICAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
EngineeringBacterial Inclusion Bodies for the Sustained and Remote Release of Tumor-Targeted Protein Drugs
Autor/es:
ISOLDA CASANOVA,; JOAQUÍN SERAS FRONDOZO; PATRICIA ÁLAMO,; MARIA VIRTUDES CESPEDES; LAURA SÁNCHEZ-GARCIA; ALEJANDRO SÁNCHEZ-CHARDI; JULIETA M. SANCHEZ; NAROA SERNA; ESTHER VÁZQUEZ; HECTOR LOPEZ LAGUNA; ANTONIO VILLAVERDE; UGUTZ UNZUETA; RITA SALA,; MIREIA PESARRODONA; OLIVIA CANO-GARRIDO; RAMÓN MANGUES
Lugar:
Taiwan
Reunión:
Congreso; 14th AsianCongressonBiotechnology (ACB2019); 2019
Institución organizadora:
Asian Federation of Biotechnology
Resumen:
Bacterial inclusion bodies (IBs) are insoluble, amyloidal protein clusters found inrecombinant bacteria 1. Formed by a combination of functional and non-functional versions of the recombinant protein 2, they act as mechanically stable, sub-micron protein materials with recognized potential in biotechnology, materials sciences and biomedicine 3. Upon intratumoral injection, IB materials are stable, showing a biological impact on surrounding tissues through the sustained release of the forming functional protein 4. When build by tumor-targeted self-assembling proteins, IBs contain assembled oligomers 5 that are slowly released from the bulk material under physiological conditions 6,7. Ifsubcutaneously implanted, such IBs slowly and steadily release functionalproteinnanoparticles that specifically reach target cells through the blood stream 8. IBs can be thus engineered to mimic the human secretory granules from the human endocrine system, for uses in precision medicine.